Filters

Term Search
You can select from the dropdown list OR enter your own terms to refine the search.

Last Updated: 10/31/2025

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 118 publications

Mosunetuzumab plus polatuzumab vedotin in transplant-ineligible refractory/relapsed large B-cell lymphoma: primary results of the phase 3 SUNMO trial.

Mosunetuzumab plus polatuzumab vedotin in transplant-ineligible refractory/relapsed large B-cell lymphoma: primary results of the phase 3 SUNMO trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 02, 2025

Characterization of anti-CD3 antibodies in clinically available bispecific T cell engagers.

Characterization of anti-CD3 antibodies in clinically available bispecific T cell engagers.

Journal: Seminars in hematology
Published: August 21, 2025

Clinical representativeness of pivotal trials for T-cell engagers in relapsed/refractory follicular lymphoma.

Clinical representativeness of pivotal trials for T-cell engagers in relapsed/refractory follicular lymphoma.

Journal: Future oncology (London, England)
Published: August 13, 2025

Richter Transformation in Chronic Lymphocytic Leukemia: Current Treatment Challenges and Evolving Therapies.

Richter Transformation in Chronic Lymphocytic Leukemia: Current Treatment Challenges and Evolving Therapies.

Journal: International journal of molecular sciences
Published: July 20, 2025

Bispecific Antibodies in Hematologic Malignancies: Attacking the Frontline.

Bispecific Antibodies in Hematologic Malignancies: Attacking the Frontline.

Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Published: July 13, 2025

Bispecific Monoclonal Antibodies in Diffuse Large B-Cell Lymphoma: Dawn of a New Era in Targeted Therapy.

Bispecific Monoclonal Antibodies in Diffuse Large B-Cell Lymphoma: Dawn of a New Era in Targeted Therapy.

Journal: Cancers
Published: July 08, 2025

Mosunetuzumab-associated fatal HHV-6 encephalitis in a patient with follicular lymphoma.

Mosunetuzumab-associated fatal HHV-6 encephalitis in a patient with follicular lymphoma.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
Published: July 08, 2025

Bispecific Antibodies-A New Hope for Patients with Diffuse Large B-Cell Lymphoma.

Bispecific Antibodies-A New Hope for Patients with Diffuse Large B-Cell Lymphoma.

Journal: Journal of clinical medicine
Published: July 03, 2025

Cost effectiveness of mosunetuzumab and CAR-T cell therapy in relapsed/refractory follicular lymphoma.

Cost effectiveness of mosunetuzumab and CAR-T cell therapy in relapsed/refractory follicular lymphoma.

Journal: Leukemia & lymphoma
Published: June 09, 2025

CD20×CD3 bispecific antibody achieved significant efficacy in patients with large B-cell lymphoma relapsing after or refractory to CAR-T therapy: a systematic review and meta-analysis.

CD20×CD3 bispecific antibody achieved significant efficacy in patients with large B-cell lymphoma relapsing after or refractory to CAR-T therapy: a systematic review and meta-analysis.

Journal: Frontiers in oncology
Published: June 05, 2025

Targeted therapies and resistance mechanisms in lymphoma: Current landscape and emerging solutions.

Targeted therapies and resistance mechanisms in lymphoma: Current landscape and emerging solutions.

Journal: Oncoscience
Published: May 29, 2025

Single-Agent and Associated Therapies with Monoclonal Antibodies: What About Follicular Lymphoma?

Single-Agent and Associated Therapies with Monoclonal Antibodies: What About Follicular Lymphoma?

Journal: Cancers
Published: March 31, 2025
Showing 1-12 of 118

Last Updated: 10/31/2025